文献速递肺外科心外重症与机械循环支持

美国COVID-19呼吸衰竭肺移植:移植后1年结局及术前体外膜氧合支持的影响

Lung transplantation for COVID-2019 respiratory failure in the United States: Outcomes 1-year posttransplant and the impact of preoperative extracorporeal membrane oxygenation support.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-04-21

基于美国器官共享联合网络(UNOS)数据库2020年8月至2022年3月305例经专家验证的COVID-19相关呼吸衰竭肺移植患者,移植后1年生存率在COVID-19相关急性呼吸窘迫综合征与COVID-19后肺纤维化之间无差异(P=.8)。术前需ECMO支持者(191例,63%)与无需ECMO者各时间点生存率无显著差异,需ECMO的COVID-19肺衰竭受者与需ECMO的非COVID-19限制性肺病受者1年生存率亦相似(84.8% vs 78.0%,P=.1)。

要点

  • 305例COVID-19相关呼吸衰竭肺移植患者移植后1年生存率在急性呼吸窘迫综合征与肺纤维化间无差异(P=.8)。
  • 191例(63%)术前需ECMO支持,其中91.2%为静脉-静脉ECMO,中位支持66天。
  • 术前需ECMO者与无需ECMO者1年生存率无显著差异(84.8% vs 90.9%,P=.2)。

核心结论

  • 研究提示,COVID-19呼吸衰竭患者肺移植可获得可接受的1年结局。
  • 尽管术后病程常更复杂,经充分选择的患者术前长时间ECMO支持与足够的临床和功能状态相关。

研究设计与样本

  • 利用美国器官共享联合网络(UNOS)专家验证记录并从UNOS数据库提取数据,评估2020年8月至2022年3月美国肺移植患者的生存、术后并发症及术前ECMO影响。
  • 共纳入305例COVID-19相关呼吸衰竭肺移植患者,其中188例为COVID-19相关急性呼吸窘迫综合征,117例为COVID-19后肺纤维化。

主要发现

  • 305例患者移植后1年生存率在COVID-19相关急性呼吸窘迫综合征与COVID-19后肺纤维化之间无差异(P=.8)。
  • 191例(63%)术前需要ECMO支持,中位支持时间66天,其中91.2%使用静脉-静脉ECMO。
  • 术前需ECMO者与无需ECMO者1个月、6个月、12个月生存率无显著差异(95.8% vs 99.1%、93.1% vs 96.4%、84.8% vs 90.9%,P=.2)。
  • 需ECMO的COVID-19肺衰竭受者与需ECMO的非COVID-19限制性肺衰竭受者1年生存率相似(84.8% vs 78.0%,P=.1)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with end-stage respiratory failure after severe coronavirus disease 2019 (COVID-19) infection may benefit from lung transplant; however, data on transplant outcomes and the impact of prolonged circulatory support before transplant in these patients are limited. METHODS: We assessed survival, postoperative complications, and the impact of pretransplant extracorporeal membrane oxygenation (ECMO) in patients undergoing lung transplant in the United States from August 2020 through March 2022 using records validated by United Network for Organ Sharing experts and extracted from the United Network for Organ Sharing database. RESULTS: In 305 patients with COVID-19-related respiratory failure and validated data, survival for up to 1-year posttransplant did not differ between 188 patients with COVID-19-related acute respiratory distress syndrome and 117 patients with post-COVID-19 pulmonary fibrosis (P = .8). Pretransplant ECMO support (median 66 days) was required in 191 patients (63%), and venovenous ECMO was used in 91.2% of patients. One-, 6-, and 12-month survival was not significantly different between patients requiring ECMO and patients without ECMO (95.8% vs 99.1%, 93.1% vs 96.4%, 84.8% vs 90.9%, P = .2) In addition, 1-year survival was similar in recipients requiring ECMO for COVID-19 lung failure and recipients requiring ECMO for non-COVID-19 restrictive lung failure (84.8% vs 78.0%, P = .1). CONCLUSIONS: These findings suggest that lung transplant in patients with COVID-19 respiratory failure yields acceptable 1-year outcomes. Despite an often more complex postoperative course, prolonged ECMO pretransplant in well-selected patients was associated with adequate clinical and functional status.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bermudez C, Bermudez F, Courtwright A, et al. Lung transplantation for COVID-2019 respiratory failure in the United States: Outcomes 1-year posttransplant and the impact of preoperative extracorporeal membrane oxygenation support. J Thorac Cardiovasc Surg. 2023. PMID: 37087098. doi:10.1016/j.jtcvs.2023.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。